Consumer Health: Treating sickle cell disease
Sickle cell disease, which is a group of inherited red blood cell disorders, affects approximately 100,000 people in the U.S., according to the Centers for Disease Control and Prevention. September is National Sickle Cell Awareness Month, which makes this a good time to learn about treating two of the most common types of sickle cell disease: sickle cell anemia and thalassemia. Sickle cell anemia Sickle cell anemia is caused by a mutation in the gene that tells your body… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 7, 2022 Category: Databases & Libraries Source Type: news
The Dying Children Divide
Sizable differences in the levels of children dying persist especially between more developed and less developed regions. Credit: Franz Chávez/IPSBy Joseph ChamiePORTLAND, USA, Sep 5 2022 (IPS) The chances of a child dying before reaching age five years have dropped substantially worldwide during the recent past. However, a significant divide remains among countries as well as within regions in the chances of children dying.
Over the past fifty years, the death rates of infants and children under age five have declined markedly. Since 1971 the world’s infant mortality rate declined from nearly 100 deaths per 1,000 live ...
Source: IPS Inter Press Service - Health - September 5, 2022 Category: International Medicine & Public Health Authors: Joseph Chamie Tags: Development & Aid Global Headlines Health Inequality Population Poverty & SDGs Source Type: news
Ghana: NHIs Now Covers Childhood Cancers, Sickle Cell Treatment - Vice President Bawumia Announces
[GhanaToday] The Treatments for childhood cancers and the cost of Hydroxyurea, an essential drug for the treatment of sickle cell anaemia, are now covered by the National Health Insurance Scheme (NHIS), Vice President Mahamudu Bawumia has announced. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 29, 2022 Category: African Health Source Type: news
Ghana: NHIS Now Covers Childhood Cancers, Sickle Cell Treatment - Vice President Bawumia
[GhanaToday] The Treatments for childhood cancers and the cost of Hydroxyurea, an essential drug for the treatment of sickle cell anaemia, are now covered by the National Health Insurance Scheme (NHIS), Vice President Mahamudu Bawumia has announced. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - August 29, 2022 Category: African Health Source Type: news
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX ® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
LOS ANGELES, August 27, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. Data were presented in the plenary session at the 19th International Myeloma Society (IMS)...
Source: Johnson and Johnson - August 28, 2022 Category: Pharmaceuticals Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Marks First Approval Worldwide for TECVAYLI ® (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma
BEERSE, BELGIUM, August 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted conditional marketing authorisation (CMA) of TECVAYLI® (teclistamab) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). Patients must have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.[1] Today’s milestone marks the first approval worldwide for teclistamab, a first-i...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
PK Modulator Shows Promise in Thalassemia
(MedPage Today) -- In a small study, the allosteric pyruvate kinase (PK) modulator mitapivat (Pyrukynd) was effective in treating hemolytic anemia in patients with α-thalassemia and β-thalassemia who are not dependent on transfusions... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 17, 2022 Category: Hematology Source Type: news
Camp Lejeune Veterans Win Justice
On Wednesday, Aug. 10, President Joe Biden signed the comprehensive Honoring Our PACT Act of 2022 into law, allowing military veterans and families harmed by contaminated water at Marine Corps Base Camp Lejeune to file lawsuits against the federal government.
The Camp Lejeune Justice Act of 2022, which focuses on four decades of water contamination, is just one part of the much broader PACT Act, which expands access to health care and disability benefits for veterans harmed by toxic exposures around the world.
Biden lauded the bipartisan support for the PACT Act at the signing.
“There are a lot of issues we can...
Source: Asbestos and Mesothelioma News - August 10, 2022 Category: Environmental Health Authors: Chris Elkins Tags: Veterans Source Type: news
Relationship between anemia and falls among postmenopausal women in Korea - Kim Y, Kim J.
This study was conducted to explore the relationship between anemia and falls in postmenopausal women. The relationships between energy, protein, iron, and vitamin C intake were also checked. The data of this study are a combination of data from the Korea ... (Source: SafetyLit)
Source: SafetyLit - July 29, 2022 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Nigeria: Dealing With Sickle Cell Disease in Modern Society
[This Day] Despite counseling by medical experts to intending couples not to marry partners with incompatible genotype so as to reduce cases of sickle cell anaemia, over 150, 000 children are born annually in Nigeria with the disease according to World Health Organisation records. Blessing Ibunge reports on the inherent challenges therein (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 28, 2022 Category: African Health Source Type: news
Anemia
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 15, 2022 Category: General Medicine Source Type: news
Mayo Clinic Q and A: What causes a high platelet count?
DEAR MAYO CLINIC: I am 33 years old and recently had an annual physical and routine blood work. I'm active with two children and feel fantastic, but my platelet count came back as 651. My health care professional said it could indicate a blood cancer and referred me to a hematologist. What can cause my platelets to be so high? I'm nervous, as my only prior medical problem was iron deficiency anemia. ANSWER: Being told you might… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - July 3, 2022 Category: Databases & Libraries Source Type: news
How Jennifer Doudna ’s Life Has Changed Since Discovering CRISPR 10 Years Ago
Jennifer Doudna was staring at a computer screen filled with a string of As, Cs, Ts, and Gs—the letters that make up human DNA—and witnessing a debilitating genetic disease being cured right before her eyes. Just a year earlier, in 2012, she and microbiologist Emmanuelle Charpentier had published a landmark paper describing CRISPR-Cas9, a molecular version of autocorrect for DNA, and she was seeing one the first demonstrations of CRISPR’s power to cure a human disease. She was in the lab of Dr. Kiran Musunuru, a Harvard researcher who was eager to show her the results from an experiment he had just finish...
Source: TIME: Health - July 1, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized feature Genetics healthscienceclimate Source Type: news
COVID-19 and Immune-Mediated RBC Destruction COVID-19 and Immune-Mediated RBC Destruction
This article summarizes the epidemiologic, clinical, and laboratory characteristics of patients with COVID-19-associated AIHA.American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 30, 2022 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news
